Overview

Location [1]
9p13.3
Pathway
DNA damage/repair
Protein [2]
Fanconi anemia group G protein
Synonyms [1]
FAG, XRCC9

Fanconi anemia, complementation group G (FANCG) is a gene that encodes a protein that is a member of the Fanconi anemia complementation group. The protein complex functions in the heterogeneous recessive disorder Fanconi anemia that causes cytogenetic instability, hypersensitivity to DNA crosslinking agents, increases chromosomal breakage, and defective DNA repair. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

FANCG is altered in 1.18% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, and melanoma having the greatest prevalence of alterations [3].

FANCG GENIE Cases - Top Diseases

The most common alterations in FANCG are FANCG Mutation (0.53%), FANCG Amplification (0.08%), FANCG A265V (0.01%), FANCG A607T (0.01%), and FANCG L306P (0.01%) [3].

FANCG GENIE Cases - Top Alterations

Significance of FANCG in Diseases

Malignant Solid Tumor +

Prostate Adenocarcinoma +

Breast Carcinoma +

Ovarian Carcinoma +

Prostate Carcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Urothelial Carcinoma +

Pancreatic Adenocarcinoma +

Endometrial Carcinoma +

Non-Small Cell Lung Carcinoma +

Pancreatic Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Cervical Carcinoma +

Non-Hodgkin Lymphoma +

Small Cell Lung Carcinoma +

Colorectal Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Cholangiocarcinoma +

Clear Cell Renal Cell Carcinoma +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Head And Neck Squamous Cell Carcinoma +

Osteosarcoma +

Soft Tissue Sarcoma +

Squamous Cell Lung Carcinoma +

Melanoma +

Colorectal Adenocarcinoma +

Malignant Intestinal Neoplasm +

Bladder Urothelial Carcinoma +

Cancer +

Bladder Carcinoma +

Malignant Esophagogastric Neoplasm +

Malignant Ovarian Epithelial Tumor +

Ampulla Of Vater Carcinoma +

Anal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Bile Duct Adenocarcinoma +

Biliary Tract Carcinoma +

Diffuse Large B-Cell Lymphoma +

Esophageal Adenocarcinoma +

Esophageal Carcinoma +

Ewing Sarcoma +

Gastric Adenocarcinoma +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Kidney Carcinoma +

Leiomyosarcoma +

Low Grade Ovarian Serous Adenocarcinoma +

Malignant Gastric Neoplasm +

Malignant Mesothelioma +

Malignant Small Intestinal Neoplasm +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mesothelioma +

Multiple Myeloma +

Neuroblastoma +

Ovarian Clear Cell Adenocarcinoma +

Pancreatic Ductal Adenocarcinoma +

Penile Carcinoma +

Rhabdomyosarcoma +

Uveal Melanoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.